Search

Your search keyword '"Rispens, Theo"' showing total 1,035 results

Search Constraints

Start Over You searched for: Author "Rispens, Theo" Remove constraint Author: "Rispens, Theo"
1,035 results on '"Rispens, Theo"'

Search Results

4. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

8. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

9. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

11. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

12. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis

13. Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines

14. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

15. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases

16. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees

18. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

19. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

21. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

26. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

27. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

28. Early model-based precision-dosing at home to guide adalimumab therapy

29. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis

31. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

32. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

33. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment.

37. CD5L is a canonical component of circulatory IgM

38. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment

39. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

40. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

41. Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling

42. The Influence of Human IgG Subclass and Allotype on Complement Activation

43. Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

44. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

45. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load

49. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

50. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.

Catalog

Books, media, physical & digital resources